Revenue segments as reported by the company.

Collaboration revenue

Grant revenue

Product sales

Other revenue

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and Development

General and Administrative

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Moderna

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Moderna reports robust earnings, eyes growth through innovative vaccines

Moderna's strong financial performance and strategic investments in R&D and commercial activities position it well for future growth. While facing challenges in product sales and regulatory uncertainties, the company's focus on innovation and expanding its product portfolio presents opportunities for continued success in the healthcare sector.

Moderna posts strong Q1 earnings, eyes market expansion opportunities

Moderna's Q1 performance reflects strong earnings, robust R&D investments, and strategic commercial negotiations.
The company's strengths lie in market positioning, cost optimization, asset prioritization, and collaboration opportunities.
Challenges include contract timing uncertainties, market competition, and regulatory approval processes.
Amidst challenges, Moderna sees opportunities in revenue growth, market expansion, program advancements, and partnership developments.

Moderna reports Q2 performance, innovation strength, margin challenges

Moderna's Q2 performance reflects significant investments and revised COVID-19 sales expectations.
The company's strengths lie in innovation, oncology progress, and preparations for upcoming product launches.
Challenges include margin guidance revisions and differing views on vaccine development strategies.
Opportunities exist in vaccine combinations, market positioning, and accelerated enrollment in flu studies.

Moderna reports $1.8B Spikevax sales, eyes profitability in 2024

Moderna's Q3 2023 Earnings Call highlighted strong Spikevax sales, plans for new vaccine launches, and a focus on profitability. Despite challenges like restructuring charges, the company sees opportunities in expanding its product portfolio and market share.

Moderna reports $6.1B in 2023 sales, anticipates $4B in 2024

Moderna's financials reflect market transition impact with a focus on cost management.
Strong pipeline progress and confidence in vaccine efficacy milestones for 2024.
Challenges include net loss, anticipated sales decrease, and ongoing regulatory discussions.
Opportunities lie in potential vaccine approvals, partnerships, and therapeutic advancements.

Moderna reports Q1 sales dip, eyes growth in pipeline

Moderna's Q1 2024 performance reflects a shift in sales dynamics with a focus on pipeline progress and financial discipline.
While facing challenges in market dynamics and transparency, Moderna's strategic focus on COVID-19 and pipeline advancements positions it for growth.
Opportunities lie in expanding vaccine delivery methods, international market penetration, and therapeutic advancements in various programs.

Moderna reports robust Q2 earnings, focuses on innovation and cost management

Moderna's Q2 2024 earnings call highlighted strong financial performance, strategic achievements in vaccine development, and operational improvements. While facing challenges in sales and competitive pressures, the company remains focused on innovation and cost management. Opportunities lie in upcoming milestones and the potential of its diverse clinical programs.

Moderna reports robust Q3 earnings, eyes global expansion and innovation

Moderna's Q3 2024 earnings call showcased strong financial performance, cost-saving initiatives, and a robust pipeline of products in development.
While facing legal challenges and market competition, the company's strategic strengths lie in market share, global expansion plans, and financial stability.
Opportunities in education, international markets, and product development position Moderna for continued growth and innovation in the healthcare sector.
Navigating challenges and leveraging opportunities will be key for Moderna to maintain its leadership in the COVID vaccine market and drive future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Moderna announces amendment to supply agreement with Switzerland for an additional 6 Million doses of COVID-19 Vaccine Moderna.

Moderna Announces Amendment to Supply Agreement with Switzerland for an Additional 6 Million Doses of COVID-19 Vaccine Moderna

Microsoft

American Tower

Amazon

Beyond Meat

Lowe's

AT&T

Stocks in companies that deliver long-term success are still the secret to wealth accumulation The post 7 Stocks to Buy for the Long Run appeared first on InvestorPlace. More From InvestorPlace Why Everyone Is Investing in 5G All WRONG Top Stock Picker Reveals His Next Potential Winner It doesn't matter if you have $500 in savings or $5 million.

7 Stocks to Buy for the Long Run

As Moderna Inc (NASDAQ: MRNA) approaches to manufacture almost one million doses a day, the company has proposed filling COVID-19 vaccine vials with additional doses of up to 15 versus 10 currently to ease the manufacturing crunch, Reuters reports. Last week CNBC reported that Moderna had asked the FDA to fill its COVID-19 vaccine vials with up to five additional doses.

Moderna Proposes Filling Vials With Additional Doses Of COVID-19 Vaccine

Advanced Micro Devices

Charter Communications

Sirius XM Holdings Inc

Tesla

Analog Devices

Check Point Software Technologies

Fox Corporation Class A

Peloton

Atlassian

These predominantly high-growth stocks are being targeted by short-sellers.

10 Nasdaq 100 Stocks With the Highest Short Interest

Johnson & Johnson

Is Moderna Stock a Buy or Sell After Johnson & Johnson's Vaccine News?

The stock price of Moderna Inc (NASDAQ: MRNA) is trading at over 2% pre-market. This is why it happened.

MRNA Stock Price Increases Over 2% Pre-Market: Why It Happened

Shares of Moderna Inc. tumbled 8.2% in trading on Monday after Bank of America analysts downgraded the company's stock to underperform from neutral, citing valuation concerns. Until December, Moderna was a clinical-stage company that had yet to bring to market a single therapy, but it now has one of two authorized COVID-19 vaccines in the U.S. The company's stock is up 52.7% so far this year and has soared 677.6% over the past 12 months.

Bank of America downgrades Moderna stock over concerns about valuation

The stock is down 9% after a valuation downgrade from Bank of America.

Moderna Stock: Buy the Dip?

Coronavirus vaccine developer Moderna Inc's (NASDAQ: MRNA) stock was moving lower Monday after a downgrade from BofA Securities.  The Moderna Analyst: Geoff Meacham downgraded Moderna shares from Neutral to Underperform and maintained a $150 price target.

Moderna Analyst: Unrealistic COVID-19 Vaccine Expectations Create Unfavorable Setup

The shares of Moderna Inc. (NASDAQ:MRNA) are lower this morning, last seen down 4.5% at $165.34, despite reports that the biopharmaceutical concern is attempting to get authorization from the Food and Drug Administration (FDA) to raise the number of doses in its Covid-19 vaccine vials to 15 from 10.

MRNA Pulls Back from Highs Despite Plans to Up Vaccine Doses

BioNTech SE

Novavax

Pfizer

Which Is the Best COVID Vaccine Stock: Pfizer, BioNTech, Moderna, Johnson & Johnson, or Novavax?

Moderna has reportedly sought approval to include up to five extra doses in each vial of its COVID-19 vaccine, a move that could speed up distribution.  The company asked the Food and Drug Administration (FDA) to allow it to include 15 doses in each vial, up from 10 doses, according to CNBC.

Moderna is seeking FDA approval to increase doses in each COVID-19 vaccine vial, reports say

Moderna asked the FDA to allow it to put more doses of its Covid-19 vaccine in each vial to alleviate a bottleneck in manufacturing.

Moderna said to seek FDA clearance to increase doses per vial to alleviate manufacturing bottleneck

Market volatility hit Wall Street again on Friday.

Tesla Falls Below $800 as Nasdaq Swoons; Moderna Gets a Boost

Inferior effectiveness of the Johnson & Johnson vaccine is unlikely to instill public confidence.

Moderna (MRNA) at High as Johnson & Johnson (JNJ) Vaccine Disappoints

New strains represent a challenge now and into the future.

Here's What You Need to Know About New COVID Strains -- and How Today's Vaccines Are Holding Up

AMC Entertainment

GameStop

One of the most common questions traders have about stocks is “Why Is It Moving?”.

Is Now The TIme To Buy Stock In Moderna, GameStop, AMC Or Express?

Doses still are scarce in some locations.

Should Investors Worry About Coronavirus Vaccine Supply?

It answered the question everyone has been asking since the start of clinical trials.

Moderna Just Eliminated One of Its Biggest Risks

This may not be a one-product company for long.

Is Moderna a Long-Term Buy?

In the healthcare industry, diligence is a matter of life and death. We're looking at you, Theranos.

Here's What Investors Need to Know About Medical Diligence

The small biotech just reported terrific news for its COVID-19 vaccine candidate.

Look Out, Pfizer and Moderna: Here Comes Novavax

What You Need to Know About COVID Vaccine Investing Right Now

Moderna's ability to create innovative formulae with its mRNA technology hints at a much greater upside for Moderna stock in the future. The post Moderna Is a ‘Buy and Hold Forever' Type of Stock appeared first on InvestorPlace.

Moderna Is a ‘Buy and Hold Forever' Type of Stock

MRNA has won the Covid-19 vaccine race and could bring in $11.7 billion with its candidate in 2021. But is Moderna stock overpriced?

News for Moderna Stock (MRNA)